Evrópusambandið - íslenska - EMA (European Medicines Agency)

tmc pharma services ltd. - gadófosveset tríatríum - magnetic resonance angiography - andstæður frá miðöldum - Þetta lyf er eingöngu ætlað til greiningar. ablavar er ætlað fyrir andstæða-auka segulómun hjartaþræðingu (ce-mra) fyrir visualisation kvið eða útlim skip í fullorðnir aðeins, með grun eða þekkt æðum.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil sweden ab - loperamidum hýdróklóríð - filmuhúðuð tafla - 2 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter holding b.v.* - calcium chloride; magnesii chloridum; sodium chloride; sodium hydrogen carbonate; kalii chloridum; disodium phosphate dodecahydrate - blóðskilunar-/blóðsíunarlausn - 1,2 mmol/l

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lyf til veikindi öndunarvegi sjúkdómum, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ferring lægemidler a/s - menotropinum - stungulyfsstofn og leysir, lausn - 1200 a.e.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ferring lægemidler a/s - menotropinum - stungulyfsstofn og leysir, lausn - 600 a.e.